Annual Report 2014 Active Biotech AB (publ)
April 30 2015 - 04:01AM
Active Biotech's Annual Report 2014 is now
available for download at www.activebiotech.com.
The Annual Report will only be
digitally distributed.
Lund, April 30, 2015
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information, please
contact:
Hans Kolam
CFO
Tel +46 (0)46 19 20 44
Active Biotech
AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties, is in pivotal phase III development
for the treatment of relapsing remitting multiple sclerosis. Also,
laquinimod is in phase II development for the treatment of primary
progressive multiple sclerosis and Huntington's disease. The
project portfolio includes a preclinical project, ISI, with the
objective to produce new, patentable chemical compounds for
treatment of diseases within the company's focus areas. Please
visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No.
556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under
the Financial Instruments Trading Act to make the information in
this press release public. The information was submitted for
publication at 10:00 a.m. CET on April 30, 2015.
Annual Report 2014 Active Biotech
AB (publ)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#1916577
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2023 to Mar 2024